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The apelins are a family of peptides1 that have an emerg-ing role in the human cardiovascular system with the most 
abundant isoform being [Pyr1]apelin-13. In healthy humans, 
the major action of infusion of apelin in the forearm was an 
increase in blood flow caused by the release of vasodilators, 
principally nitric oxide.2 In agreement, in vitro studies in 
human isolated vessels show that apelin is a potent vasodila-
tor.3,4 Apelin binds to a single G-protein coupled receptor (also 
known as APJ).5 The vasodilatation and inotropic actions of 
apelin at this receptor make it an attractive target for devel-
opment of new therapies for heart failure6–9 and pulmonary 
arterial hypertension,10–13 conditions in which the apelin sys-
tem is reportedly downregulated, using agonists to replace the 
missing apelin. A fundamental limitation of many agonists 
acting at G-protein coupled receptors, such as apelin, is that 
after stimulating G-protein pathways to elicit a physiological 
response, the target receptor is internalized14–17 and silenced via 
the β-arrestin pathway.14 Furthermore, although apelin activa-
tion of the Gαi-protein pathway elicits a protective response 
in the heart, in the absence of apelin, stretch signals through 
the apelin receptor are mediated via β-arrestins resulting in 
detrimental cardiac hypertrophy.18 Evidence is emerging that 
agonists acting at the same receptor can be engineered to sta-
bilize different conformational states and selectively stimulate 
either the G-protein (eg, μ-opioid receptor)19 or β-arrestin (eg, 
angiotensin AT1 receptor)20 pathway and function as biased 
agonists.20,21
We hypothesized that an agonist at the apelin receptor 
designed to display bias toward the G-protein pathway would 
produce vasodilatation and increased cardiac output with 
reduced loss of efficacy owing to receptor downregulation. 
We have simulated apelin and cyclic apelin peptide analogs 
in aqueous solution and also used homology modeling and 
molecular dynamics simulations of apelin with its receptor 
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to design ≈105 cyclic peptide analogues. These were tested 
for inhibition of radiolabelled apelin binding followed by a 
screening cascade comparing G-protein–dependent versus 
G-protein–independent pathways to identify a biased agonist, 
MM07. As proof of principle in first-in-human studies, we 
show MM07, as predicted, is a more effective vasodilator in 
human vasculature than apelin and increases cardiac output in 
rodent by echocardiography.
Methods
Additional information is available in the online-only Data 
Supplement. Animal experiments were performed according to local 
ethics committee (Universities of Cambridge and London) and Home 
Office (UK) guidelines under the 1986 Scientific Procedures Act.
Computational Methods
From analysis of molecular dynamics simulations, MM07 (cyclo[1–
6]CRPRLCHKGPMPF) was expected to mimic the solution confor-
mation of apelin-13 (NH
2
-QRPRLSHKGPMPF-COOH) and promote 
a β-turn conformation at the RPRL motif, suggested to be important 
for initial recognition and binding at the apelin receptor.22–24
Simulation Protocol
The model of MM07 was constructed using the Biopolymer module 
of the Sybyl 7.3 program25 and energy minimized in vacuo with the 
Amber11 FF99SB force field.26 Gromacs version 3.3.127-29 was used 
for all simulations. Replica exchange molecular dynamics30 was used 
to explore the conformational space of the peptides.
Homology Modeling of the Apelin Receptor
The modeling template was based on the 2.5 Å resolution crystal struc-
ture of the human CXCR4 chemokine receptor. MODELLER9v8 was 
used to generate homology models of apelin and subsequently refined 
using molecular dynamics.
Human Tissue Collection
Human tissues were obtained with informed consent (Papworth 
Hospital Research Tissue Bank REC08/H0304/56) and experi-
ments performed with local ethical approval (REC05/Q0104/142). 
Saphenous vein was from 19 patients receiving coronary artery 
bypass grafts. Heart tissues were from 3 patients undergoing cardiac 
transplantation.
Competition Binding Assays
Initial assays were performed in cells expressing the human apelin 
receptor (CHO-K1-APJ cells; Cerep, Celle L’Evescault, France). In 
subsequent experiments, homogenate of human left ventricle was 
incubated with 0.1 nmol/L [Glp65,Nle75,Tyr77][125I]apelin-13 and with 
[Pyr1]apelin-13 or MM07 (0.01 nmol/L–100 μmol/L). Nonspecific 
binding was defined using 1 μmol/L [Pyr1]apelin-13. Data were ana-
lyzed (KELL package; Biosoft, UK) to obtain the dissociation con-
stant K
D
 (concentration of ligand occupying 50% of receptors).
Cell-Based Functional Assays
β-Arrestin and receptor internalization assays (AGTRL1; DiscoveRx, 
Fremont, CA) used cells expressing the human apelin receptor. 





 of the EC
50
 [the concentration of agonist pro-
ducing 50% of maximum response]) and maximum response (E
MAX
) 
for [Pyr1]apelin-13 and MM07.
Human Saphenous Vein Contraction Study
The predominant effect of apelins in vivo is vasodilatation2 and ape-
lin peptides are equi-effective dilators of human endothelium-intact 
arteries in vitro.3 However, removal of the endothelium in saphenous 
vein unmasks apelin contraction,3 which we have exploited as a 
routine bioassay. Cumulative concentration–response curves to [Pyr1]
apelin-13 and MM07 (10−12 to 10−7mol/L) were expressed as a percent 
of the maximum response to 100 mmol/L KCl. Data were analyzed as 
described for the cell based assays.
Analysis of MM07 Signaling Pathway Bias
Data from in vitro assays were analyzed as previously described31 to 
determine the pathway signaling profile for MM07 compared with 
[Pyr1]apelin-13 to show whether MM07 exhibited additional bias for 
the individual signaling pathways investigated.
In Vivo Plasma Half-Life of Apelin Peptides
Rats (230–260 g), anaesthetized with 2% isoflurane, were given a 
single intravenous bolus (600 nmol) of apelin or MM07 (both n=3). 
Arterial blood samples were taken over the subsequent 30 minutes 
and plasma concentrations measured using an enzyme immunoassay 
that detects both peptides, and plasma half-life was determined.
Systemic Infusions in Rat
Surgical preparation and experimental techniques were as described 
previously.32 After baseline measurements, male Wistar rats (300±25 
g body weight) received vehicle (300 μL bolus), then incremental 
doses of [Pyr1]apelin-13 or MM07 (1–300 nmol/300 μL), followed 
by S-Nitroso-N-acetyl-d,l-penicillamine (SNAP). Blood pressure 
(BP) was monitored continuously via an intra-arterial line and echo-
cardiography was used after each bolus to determine changes in heart 
rateHR, stroke volume, cardiac output (from peak velocity and veloc-
ity time interval) and respiratory rate. Rectal temperature was moni-
tored throughout. BP was analyzed using absolute change in mean 
BP from the baseline taken just before the bolus and area under the 
curve analysis.
Human Volunteer Studies
All volunteers (n=12 forearm plethysmography, n=10 hand vein stud-
ies) gave written informed consent, and studies adhered to the princi-
ples of the Declaration of Helsinki and were approved by the National 
Research Ethics Service Committee East of England–Cambridge 
Central (REC 11/EE/0305).
Forearm Venous Occlusion Plethysmography
[Pyr1]apelin-13 and MM07 were infused in 3 incremental doses, 6 
minutes each, using the previously determined optimal dose range. 
The order of peptides was randomized, separated by 20 minutes 
saline infusion, and the study completed by infusion of sodium 
nitroprusside (3 µg/min for 6 minutes) or saline. Forearm blood flow 
(FBF) was measured in both arms and expressed as absolute change 
in FBF in response to agonists. In a second study (n=4), the effect of 
repeated (3 doses, each for 8 minutes) infusions of MM07 was deter-
mined after a 30 minute saline washout.
Aellig Hand Vein Technique Study
After baseline measurements, norepinephrine (1–60 ng/min) was 
infused in 7 minute increments (7.5 mL/h) to achieve a stable con-
striction of 50% to 80%. [Pyr1]apelin-13 or MM07 (4 incremental 
doses, each for 8 minutes at 7.5 mL/h) were infused 30 minutes later, 
with measurements taken in the last 2 minutes of each infusion period 
followed by a 30 minute saline infusion.
Statistical Analysis
For in vivo animal and human volunteer studies, variables are 
reported as mean±standard error of the mean. Data were analyzed 
using 1- or 2-way ANOVA or 2-way repeated measures ANOVA. Post 
hoc multiple comparisons were made using Sidak’s or Tukey’s post 
hoc test as appropriate (Graph-Pad Prism; Graph-Pad Software Inc, 
San Diego, CA). Student’s 2-tailed t test was also used as appropriate. 
Statistical significance was taken at the 5% level.
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Results
Design and Conformation of MM07
To investigate the receptor bound conformation of MM07, 
compounds were initially docked into a receptor homology 
model and the complex refined using molecular dynamics. The 
apelin and MM07-apelin receptor binding poses are shown in 
Figure 1 taken from the most representative structure of the 
principal cluster of the MD simulation trajectory. The results 
implied sufficient volume was available for the cyclized pep-
tide to occupy a similar binding pose to apelin-13.
MM07 Binds to the Human Apelin Receptor
MM07 competed with nanomolar affinities for binding of 
[Glp65,Nle75,Tyr77] [125I]apelin-13 to human apelin receptors in 
CHO-K1 cells (K
D




MM07 Is a G-Protein Pathway Biased Agonist In 
Vitro
In the β-arrestin (Figure 2A) and internalization (Figure 2B) 





=6.16±0.07, n=3) was ≈790- and ≈215- fold less 





=8.49±0.1, n=3), respectively. However, 
in the saphenous vein contraction assay, the 2 peptides had 
comparable potency (pD
2
 values: [Pyr1]apelin-13, 9.93±0.24, 
n=11; MM07 9.54±0.42, n=11) and maximum response 
(E
MAX
 as %KCl: [Pyr1]apelin-13, 22%±4%; MM07, 17%±3%; 
Figure 2C). Comparing the relative effectiveness of MM07 
to activate the G-protein pathway, saphenous vein contrac-
tion compared with the non-G-protein–dependent β-arrestin 
and internalization pathways yielded bias factors for MM07 
compared with [Pyr1]apelin-13 of 1374 and 353, respectively 
(Table).
Half-Life of [Pyr1]apelin-13 and MM07
Plasma half-life of MM07 was 17.4±0.40 minutes compared 
with 2.3±0.51 minutes for [Pyr1]apelin-13 (P<0.05, 2-tailed 
Student’s t test).
MM07 Increases Cardiac Output in Rat
There was a trend to increase in cardiac output with the high-
est dose of [Pyr1]apelin-13, which corresponded to a signifi-
cant drop in BP (Figure 3A and 3B) and systemic vascular 
resistance (Figure S3B in the online-only Data Supplement). 
In contrast, MM07 caused a dose-dependent increase in car-
diac output (ANOVA versus baseline, P=0.0074; Figure 3A), 
and although there was a decrease in vascular resistance 
(Figure S3B), this was without corresponding effects on BP 
(Figure 3B). Administration of SNAP produced a profound 
fall in BP in both [Pyr1]apelin-13 and MM07-treated groups; 
however, although cardiac output was significantly increased 
in response to SNAP in the MM07 group, it was significantly 
reduced in the [Pyr1]apelin-13 group. Neither peptide caused 
a significant change in heart rate (Figure 3C), respiratory rate 
(Figure 3D), or temperature (not shown). Both [Pyr1]ape-
lin-13 and MM07 increased peak velocity above basal levels 
(ANOVA versus baseline P=0.046 and P=0.01, respectively; 
Figure 3E and 3F).
MM07 Is a Vasodilator in Human Forearm Venous 
Occlusion Plethysmography Studies
[Pyr1]apelin-13 (Figure 4A) and MM07 (Figure 4B) produced 
a significant dose-dependent increase in FBF compared with 
baseline (ANOVA P<0.01). [Pyr1]apelin-13 at 100 nmol/min 
produced an increase in FBF in the control arm. This was not 
seen with MM07 (data not shown). Importantly, the maximum 
dilatation to MM07 was approximately double that seen with 
Figure 1. Representation of the overlap between the calculated 
poses of apelin-13 (red) and MM07 (blue) binding to the apelin 
receptor. The disulphide bond of MM07 is indicated in stick, the 
side chains in lines, and the backbone in cartoon representation. 
The transmembrane helices of the apelin receptor are indicated 
by roman numerals.
Figure 2. Comparison of in vitro functional activity of [Pyr1]apelin-13 (■) and MM07 (●) in G-protein-independent (A) β-arrestin recruitment 
and (B) receptor internalization assays and G-protein-dependent (C) saphenous vein contraction assay.
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[Pyr1]apelin-13, consistent with a more efficacious action of 
the biased agonist. Repeated dose–response curves to MM07 
produced the same increase in FBF (ANOVA P=0.983), which 
was significant at 100 nmol/min for both; washout was com-
plete and no desensitization was observed (Figure 4C).
MM07 Reverses Norepinephrine Tone in the 
Human Hand Vein (Aellig Technique Study)
The dose of norepinephrine required to produce a similar 
degree of preconstriction (62.3%±3.4%) ranged from 2 to 60 
nmol/min. Compared with control data from the same volun-
teers, there was a significant reversal of norepinephrine con-
striction to [Pyr1]apelin-13 at 100 nmol/min and MM07 at 10 
and 100 nmol/min (Figure 4D).
Discussion
This is the first study to examine the in vivo effects of a novel 
synthetic biased agonist, MM07, at the apelin receptor in 
human volunteers.
MM07 and Peripheral Arterial Tone
[Pyr1]apelin-13 (1–10 nmol/min) produced a significant 
increase in FBF similar to that reported previously for 0.3–3 
nmol/min.33 At 100 nmol/min, there was no further response 
but some evidence of dilatation in the control arm, suggesting 
spillover at this highest dose tested. MM07 caused rapid and 
significant peripheral arterial dilatation. Although higher con-
centrations of MM07 were required, there was no evidence at 
any dose of effects in the control arm, and indeed it is possible 
that the rapid increase in flow in response to MM07 effec-
tively resulted in dilution of the peptide that may explain the 
apparent need for higher concentrations in the forearm com-
pared with the hand vein relative to [Pyr1]apelin-13. This is 
supported by the observation that at the 2 higher doses, the % 
increase in blood flow from baseline was double that of [Pyr1]
apelin-13, suggesting that MM07 is an effective arteriolar dila-
tor and may be a useful tool compound for use in further stud-
ies. Plasma half-life for MM07 in rat was significantly longer 
than that of [Pyr1]apelin-13. Previous studies have reported 
rapid and prolonged apelin receptor internalization14,17 after 
exposure to endogenous apelin, consistent with rapid removal 
from the plasma. The longer half-life of MM07 may there-
fore reflect reduced internalization as indicated by our in vitro 
assays. Crucially, following MM07, forearm circumference 
returned to baseline and a second incremental exposure to 
MM07 produced the same vasodilatory response; no desen-
sitization was seen. This is consistent with our in vitro assays 
showing MM07 causes reduced internalization compared with 
[Pyr1]apelin-13.
MM07 and Venous Tone
Responses in resistance and capacitance vessels do not always 
correlate; we therefore conducted further studies in peripheral 
veins. After the arterial studies, we repeated the dose rang-
ing for both peptides and performed our definitive studies at 
a higher dose range than previously reported.2 In the human 
hand vein, MM07 and [Pyr1]apelin-13 reversed an established 
norepinephrine constriction and significantly increased flow 
in the venous bed with no adverse events observed. In con-
trast to arterial studies, both peptides were equally effective 
in the vein comparable to our in vitro contraction assay. The 
magnitudes of the responses were comparable with acetylcho-
line and sodium nitroprusside, producing significant reversal 
of preconstriction.34,35 MM07 is therefore an effective periph-
eral venodilator. The effects of apelin peptides on the central 
capacitance vessels have not been tested, and further studies 
are required to determine the in vivo effects of endogenous 
apelin and related peptides on the systemic vasculature.
Systemic Effects of MM07 in Rat
Apelin is reported to be the most potent inotropic agent mea-
sured in human isolated heart in vitro3 with significant effects 
on cardiac contractility in in vivo animal models,36,37 includ-
ing ischemic cardiomyopathy38 and myocardial injury.39 The 
hemodynamic goals in patients with ventricular failure sec-
ondary to pulmonary hypertension are decreased pulmonary 
vascular resistance and augmented cardiac output, which may 
potentially be achieved with an apelin agonist. Importantly, 
in heart failure patients, systemic infusion of [Pyr1]apelin-13 
caused a beneficial peripheral and coronary vasodilatation with 
increased cardiac output.33 These actions were sustained in the 
presence of angiotensin II and sodium depletion.40 To explore 
the systemic effects of MM07 safely, we used hemodynamic 
measurements and echocardiography in rats. Echocardiography 
Table.  Estimation of G-Protein Pathway Bias for MM07 
Compared With [Pyr1]apelin-13 in Saphenous Vein Contraction, 




 LogR 10.18±0.23 10.44±0.21
 ∆LogR 0.00±0.33 0.26±0.31
 RE 1 1.82
β-Arrestin assay
 LogR 8.59±0.11 5.71±0.10
 ∆LogR 0.00±0.16 −2.88±0.15
 RE 1 0.0013
Internalization assay
 LogR 8.45±0.08 6.17±0.07
 ∆LogR 0.00±0.12 −2.29±0.11
 RE 1 0.0052
Contraction vs β-arrestin
 ∆∆LogR 0.00±0.36 3.14±0.35
 Bias factor 1 1374
Contraction vs internalization
 ∆∆LogR 0.00±0.35 2.55±0.33
 Bias factor 1 353
β-Arrestin vs internalization
 ∆∆LogR 0.00±0.19 −0.59±0.19
 Bias factor 1 0.26
LogR=Log10(τ/KA), where τ is a measure of agonist efficacy and KA is the 
agonist functional affinity (see van der Westhuizen et al31). RE indicates relative 
effectiveness; and SV, saphenous vein.
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is the mainstay of the noninvasive assessment of cardiac func-
tion in rodent models and has the advantage of clear translation 
to humans in whom the same parameters are used. In our study, 
[Pyr1]apelin-13 augmented cardiac output that was accom-
panied by significant hypotension, whereas MM07 caused a 
significant increase in cardiac output without any evidence 
Figure 3. Response to [Pyr1]apelin-13 (■, n=6) and MM07 (●, n=5) in anaesthetized rats showing changes in cardiac output (CO; A), 
change in blood pressure (BP) from baseline (B), heart rate (HR; C), and respiratory rate (RR; D). Echocardiograms showing an increase 
in peak velocity across the left ventricular outflow tract after bolus administration of [Pyr1]apelin-13 (E) and MM07 (F). Horizontal line 
indicates baseline (BL) peak velocity. Significantly different from baseline *P<0.05, **P<0.01 or [Pyr1]apelin-13 #P<0.05 (ANOVA).
Figure 4. Absolute change in forearm blood flow (FBF) during intrabrachial infusion of [Pyr1]apelin-13 (A) and MM07 (B). C, Repeated 
doses of MM07 produce a significant and reproducible response to 100 nmol/min (P<0.05). D, Concentration-dependent dilatation in 
dorsal hand veins after infusions of [Pyr1]apelin-13, MM07, and saline control. Significantly different from baseline *P<0.05, **P<0.01 
(ANOVA).
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of positive chronotropy or hemodynamic instability, and the 
inotropic effects were comparable with commonly used ino-
tropes, such as dobutamine, milrinone, and isoprenaline.41–43 
Some of the apparent cardiac effect of [Pyr1]apelin-13 may be 
attributable to a reduction in afterload secondary to peripheral 
vasodilatation, shown by the drop in BP and systemic vascular 
resistance (Figure S3B). In contrast, MM07 did reduce vascu-
lar resistance (though to a lesser extent than [Pyr1]apelin-13), 
but had no effect on BP or heart rate; we hypothesize that this 
may be as a result of an additional load-independent inotropic 
effect. In support of our hypothesis, in isolated perfused rat 
heart and paced human atrial tissue, apelin caused a sustained 
increase in contractility,3,36 independent of preload and auto-
nomic reflexes. This is predicted to occur by increasing the cal-
cium sensitivity of the contractile machinery via activation of 
myosin light chain kinase.44
Apelin Agonists in Cardiovascular Disease?
Data suggest that activating the apelin pathway may be 
valuable in conditions, such as heart failure and pulmonary 
arterial hypertension. After an initial rise in the early stages 
of heart failure, plasma levels of peptide tend to decrease 
in later stages.6–8 Although there is downregulation of the 
apelin receptor pathway in the human heart,6,9 the favorable 
systemic actions of apelin on peripheral vasodilatation and 
cardiac output remain.40 In patients with pulmonary arterial 
hypertension, >70% have reduced bone morphogenetic pro-
tein receptor-2.45 Disruption of a bone morphogenetic pro-
tein receptor-2–mediated transcriptional complex between 
PPARγ and β-catenin reduced apelin levels in pulmonary 
arterial endothelial cells from pulmonary arterial hyperten-
sion patients,10 and apelin deficiency also causes prolifera-
tion in smooth muscle cells.11 Apelin-null mice developed 
more severe pulmonary hypertension compared with wild-
type when exposed to chronic hypoxia,12 and crucially injec-
tions of apelin attenuated myocardial hypertrophy in the 
monocrotaline-treated rat.13 We therefore speculate that ape-
lin agonists, such as MM07, that may have a sustained effect 
at the apelin receptor would be beneficial in these conditions.
Perspectives
The results suggest that agonists acting at the apelin recep-
tor can preferentially stimulate the G-protein pathway over 
β-arrestin, which can translate to improved efficacy in the 
clinic. The use of biased agonists to selectively stimulate 
vasodilatation and inotropic action but avoid activating the 
β-arrestin–dependent stretch response within the heart18,46 rep-
resents a new therapeutic strategy in the treatment of cardio-
vascular disease.
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What Is New?
•	We report the discovery and first in human in vivo characterization of 
MM07, a biased agonist for the apelin receptor.
What Is Relevant?
•	The apelin system is downregulated in pulmonary arterial hypertension 
and heart failure; therefore. targeting the apelin receptor using novel 
agonists is an attractive therapeutic strategy.
Summary
Our results suggest that apelin agonists that preferentially stimulate 
G-protein over β-arrrestin pathways could translate into improved 
clinical efficacy by selectively stimulating beneficial vasodilata-
tion and inotropic actions but avoiding detrimental β-arrestin-
dependent pathways, such as the stretch response in the heart.
Novelty and Significance
